Annual report pursuant to Section 13 and 15(d)

Dispositions - Additional Information (Details)

v3.10.0.1
Dispositions - Additional Information (Details) - USD ($)
 1 Months Ended 12 Months Ended
Nov. 04, 2015
Feb. 28, 2017
Dec. 31, 2018
Dec. 31, 2017
Mar. 31, 2017
Asset Purchase Agreement and Ology Bioservices License Agreement [Member]          
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]          
Cash payments from Ology Bioservices   $ 4,500,000      
Number of shares removed from obligation to issue of common stock   23,008      
Contingent upon achieving certain specified future operating objectives   $ 3,000,000      
Amount entitled to receive     $ 4,600,000   $ 1,600,000
Milestone payment earned   $ 3,000,000      
Amount received from sale of discontinued operation     $ 2,400,000 $ 2,200,000  
Biodefense Business [Member]          
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]          
Sales of business, number of common stock shares eligible to receive 23,008        
Royalties receivable percentage on net sales 15.00%        
Biodefense Business [Member] | Maximum [Member]          
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]          
Cash payments from Ology Bioservices $ 4,500,000